Trial · NCT06270966
Cognitive Remediation VR Tool for People With MCI: a Feasibility RCT
NCT06270966, Not applicable, Unknown, University of Cagliari
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Cognitive Remediation VR Tool for People With MCI: a Feasibility RCT. Trials, record NCT06270966. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06270966
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Cognitive Remediation VR Tool for People With MCI: a Feasibility RCT
- NCT number
- NCT06270966
- Status
- Unknown
- Phases
- Not applicable
- Enrollment
- 30 participants, estimated
- Lead sponsor
- University of Cagliari
- Conditions
- Mild Cognitive Impairment, Cognitive Remediation, Virtual Reality, Psychiatric Rehabilitation
- Interventions
- Virtual Reality Cognitive Remediation
- First posted
- 2024-02-21
- Last updated
- 2024-02-21
Source ClinicalTrials.gov
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Side effects; Dropout rates; Proportion of recruited participants among those considered eligible | T0 (0 weeks); T1 (12 weeks) | Feasibility will be assessed based on tolerability, including dropout rates and acceptability, which considers the proportion of recruited participants among those considered eligible and side effects. |
| Secondary | Short Form Health Survey, 12 items (SF-12) | T0 (0 weeks); T1 (12 weeks); T2 (36 weeks); (72 weeks) | Preliminary measures of effectiveness on quality of life, 12 items |
| Secondary | Brief Social Rhythms Scale (BSRS) | T0 (0 weeks); T1 (12 weeks); T2 (36 weeks); (72 weeks) | Preliminary measures of effectiveness on biological and social rhythms, 10 items |
| Secondary | Patient Health Questionnaire (PHQ-9) | T0 (0 weeks); T1 (12 weeks); T2 (36 weeks); (72 weeks) | Preliminary measures of effectiveness on depressive symptoms, 9 Items |
| Secondary | Generalized Anxiety Disorder-7 item (GAD-7) | T0 (0 weeks); T1 (12 weeks); T2 (36 weeks); (72 weeks) | Preliminary measures of effectiveness on anxiety, 7 items |
| Secondary | Addenbrooke's Cognitive Examination (ACE-R) | T0 (0 weeks); T1 (12 weeks); T2 (36 weeks); (72 weeks) | Preliminary measures of effectiveness on general cognitive functions, the neuropsychological tests is used to identify cognitive impairment in conditions such as dementia. |
| Secondary | Matrix test | T0 (0 weeks); T1 (12 weeks); T2 (36 weeks); (72 weeks) | Preliminary measures of effectiveness on attention |
| Secondary | Rey's Word Test | T0 (0 weeks); T1 (12 weeks); T2 (36 weeks); (72 weeks) | Preliminary measures of effectiveness on memory |
| Secondary | Trail Making Test (TMT) | T0 (0 weeks); T1 (12 weeks); T2 (36 weeks); (72 weeks) | Preliminary measures of effectiveness on executive function |
| Secondary | Digit Span | T0 (0 weeks); T1 (12 weeks); T2 (36 weeks); (72 weeks) | Preliminary measures of effectiveness on memory |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests4
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Digit Span Test | Secondary outcome | ConductCognition |
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
| Trail Making Test A | Secondary outcome | ConductCognition |
| Trail Making Test B | Secondary outcome | ConductCognition |
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06270966
GET https://conductscience.org/api/trials/v1/NCT06270966/registered